Stelara (Ustekinumab) Biosimilar Status in 2026
By 2026, Stelara (ustekinumab) is expected to face increased competition from biosimilars, following patent expirations and the potential for regulatory approvals. While the exact landscape by 2026 is subject to ongoing patent challenges and regulatory timelines, several key developments are anticipated.
When Might Stelara Patents Expire?
Stelara's primary patents have been subject to various legal challenges. While the initial patent for ustekinumab expired in 2023, secondary patents related to methods of use and formulations have extended market exclusivity. However, a key patent, U.S. Patent No. 7,790,102, which has been central to litigation, was invalidated in 2023. Further legal battles and appeals could influence the precise timeline for patent expiry and subsequent biosimilar market entry. Information on patent expiry timelines can be found on DrugPatentWatch.com [1].
What is the Current Status of Ustekinumab Biosimilars?
Several companies have been developing ustekinumab biosimilars. For instance, in the United States, the Food and Drug Administration (FDA) approved the first ustekinumab biosimilar, Stelreza (Ustekinumab-aekp) by Celltrion, in October 2023 [2]. This approval marked a significant step towards market competition. Other biosimilar candidates are in various stages of development and regulatory review.
Can Biosimilars Enter the Market Before Patent Expiry?
Typically, biosimilars can only enter the market after key patents have expired or have been successfully challenged. The invalidation of certain patents for ustekinumab has opened avenues for biosimilar companies to seek regulatory approval and launch their products. However, ongoing litigation can create uncertainty regarding the exact launch dates.
How Do Ustekinumab Biosimilars Compare to Stelara?
Biosimilars are highly similar to their reference biologic drugs in terms of safety, purity, and potency. They are approved based on demonstrating no clinically meaningful differences from the reference product. Therefore, ustekinumab biosimilars are expected to offer similar therapeutic benefits and side effect profiles as Stelara, providing a comparable treatment option.
Who Are the Key Players Developing Ustekinumab Biosimilars?
Companies actively involved in the development of ustekinumab biosimilars include Celltrion, which has had its product approved [2], as well as Amgen and Samsung Bioepis. Other pharmaceutical firms may also be pursuing biosimilar development for this therapy.
What is the Expected Impact of Biosimilars on Stelara's Price?
The introduction of biosimilars is generally expected to increase competition and drive down the cost of treatment. This could lead to significant savings for healthcare systems and patients. The extent of price reduction will depend on the number of biosimilars that enter the market and the pricing strategies adopted by manufacturers.
What are the Regulatory Requirements for Biosimilar Approval?
To gain FDA approval, biosimilar developers must demonstrate a high degree of similarity to the reference product through analytical studies, animal studies, and clinical studies, including pharmacokinetic and pharmacodynamic studies, and immunogenicity studies. The regulatory pathway aims to ensure that biosimilars are safe and effective for their intended use.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-with-reference-product-labeling